Pharmaceuticals

Global Nuclear Medicine Radioisotopes Market 2026 progressing steadily toward $12.75 billion by 2030 at a 7.4% CAGR

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Nuclear Medicine Radioisotopes Market Projected To Become By 2030 Based On Its 2026 Valuation?

The market for nuclear medicine radioisotopes has demonstrated robust expansion recently. This market is projected to expand from $8.85 billion in 2025 to $9.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by the extensive application of technetium-99m in diagnostic imaging, increasing uptake of nuclear cardiology procedures, the rising incidence of cancer and thyroid conditions, the enlargement of nuclear medicine departments within hospitals, and the initial successful clinical outcomes of radioisotope-based treatments.

The nuclear medicine radioisotopes market is projected to experience substantial growth in the upcoming years, reaching $12.75 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period is fueled by several factors, including an increased demand for personalized cancer treatments, a surge in the application of lutetium-177 and actinium-225 therapies, the broadening of PET imaging infrastructure, increased capital expenditure in cyclotron and reactor facilities, and the growing acceptance of nuclear medicine in developing nations. Key trends anticipated for this period encompass the increasing integration of theranostics within oncology, a heightened need for PET and SPECT imaging, expanded utilization of targeted alpha and beta emitters, the spread of nuclear medicine applications into cardiology and neurology, and an intensified emphasis on localized radioisotope manufacturing.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

What Drivers Are Shaping The Future Growth Of The Nuclear Medicine Radioisotopes Market?

The increasing prevalence of cardiovascular diseases is anticipated to propel the expansion of the nuclear medicine radioisotope market in the future. Cardiovascular diseases encompass various ailments that impact the heart and blood vessels. The rise in these cases is attributed to sedentary lifestyles, poor dietary habits, escalating rates of obesity, and aging populations. Nuclear medicine radioisotopes prove invaluable in the diagnosis, evaluation, and management of cardiovascular diseases by offering detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnosis and effective treatment planning. For instance, in January 2024, as per the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the growing instances of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.

What Segment Groups Are Identified Within The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment

9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Trends Are Advancing Progress In The Nuclear Medicine Radioisotopes Market?

Major companies in the nuclear medicine radioisotopes market are concentrating on developing innovative solutions, such as next-generation theranostic radiopharmaceuticals, to improve precision imaging and targeted treatment. These advanced theranostic radiopharmaceuticals are sophisticated radioactive agents designed to both detect and accurately treat diseases by specifically targeting cells in the body with high precision. For instance, in November 2025, the University of California, a US-based research university, inaugurated a completely independent Department of Nuclear Medicine & Theranostics, rather than keeping nuclear medicine under the broader radiology scope. This new department aims to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and foster innovations in theranostic treatments.

Which Companies Hold Significant Positions In The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Read the full nuclear medicine radioisotopes market report here:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Which Geographic Regions Are Influencing Demand In The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nuclear Medicine Radioisotopes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

Browse Through More Reports Similar to the Global Nuclear Medicine Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Nuclear Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795